January 12, 2024 | BALTIMORE – Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the Complete Omics family as our Chief Scientific Officer (CSO) and Director for the Center for Advanced Proteomics. Dr. Zhang, a founding member of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), brings to our team a rich legacy of innovation and leadership in proteomics, especially known for her pioneering work in multi-omics studies on human cancers and her revolutionary innovation on the methods in studying N-Glycosylation on proteins.
Dr. Zhang’s biography reads like a chronicle of achievements in the scientific community. As a Professor of Pathology, Oncology, Chemical and Biomolecular Engineering, and Urology, and the Director of Mass Spectrometry Core Facility and Proteomic Research, as well as the Director for Center for Biomarker Discovery and Translation at Johns Hopkins University, her career has been dedicated to pushing the boundaries of proteomics.
Graduating from Peking University with BS and MS degrees and earning a Ph.D. from the University of Pennsylvania, Dr. Zhang’s early work at New England Biolabs and Cell Signaling Technology led to the development of novel antibodies for protein post-translational modifications (PTMs). She is the inventor behind the method for proteomic characterization of protein modifications using PTM-antibodies and the immunoaffinity isolation of modified peptides from complex mixtures.
At the Institute for Systems Biology, she pioneered glycoproteomic technology, making significant strides in the discovery of therapeutic targets and biomarkers for cancer. Her tenure at Johns Hopkins University further solidified her status as a leader in the field, with her work on glycoproteomic methods for quantitative site-specific glycosylation characterization and glycan imaging leading to numerous patents and over 300 publications in prestigious journals.
Dr. Zhang’s contributions to the fields of quantitative proteomics, glycoproteomics, targeted proteomics, and proteogenomics have not only enriched scientific understanding but have also paved the way for groundbreaking advancements in cancer research and beyond. Her work, cited over 27,000 times, reflects the depth of her impact on the global scientific community.
Her addition to Complete Omics Inc. as CSO and Director for the Center for Advanced Proteomics is a testament to our commitment to excellence and innovation. Dr. Zhang’s visionary leadership and unparalleled expertise promise to propel us into new horizons of discovery and application in omics research.
Please join us in warmly welcoming Dr. Hui Zhang to our team. With her at the helm of our scientific endeavors, we look forward to embarking on a journey filled with breakthroughs and achievements that will continue to shape the future of biomedical research and healthcare.
Discover more about the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and Dr. Zhang’s role in advancing cancer research: CPTAC Overview
